FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
What happened
In December 2025, FDA reviewed https://www.joinbelle.com and found it offered compounded semaglutide and tirzepatide drug products. The pictured labels show “Belle,” which FDA says falsely suggests Belle is the compounder when it is not. FDA calls the products misbranded, meaning their labeling is false or misleading.
What FDA found
The website labels for compounded semaglutide and tirzepatide show “Belle,” which FDA says falsely suggests Belle is the compounder.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)FDA says Belle’s advertising or promotion of these compounded drugs is false or misleading.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says the misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA also says receiving or delivering misbranded drugs in interstate commerce is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, Belle must send FDA a written response describing steps taken to fix the violations, prevent recurrence, identify who makes the compounded products, provide sample labeling, and address or remove the misleading website claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and their marketing partners
- brands whose names appear on labels they do not manufacture
This is a summary. Read the original letter on fda.gov.